Compare Enveric Biosciences Inc (ENVB) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs J M Smucker Co — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while J M Smucker Co trades at $119.26 (market cap $12.38B). The key difference: J M Smucker Co is far larger — about 1850.5× Enveric Biosciences Inc's market cap, and J M Smucker Co pays a 3.86% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and J M Smucker Co for 74 Days on average.
| ENVB | SJM | |
|---|---|---|
Market Cap | $6.69M | $12.38B |
Volume | 41,141 | 1,013,558 |
Sector | Health | Consumer Staples |
52-Week High | $10.80 | $132.34 |
52-Week Low | $1.27 | $89.53 |
Typical Hold Time | 14 Days | 74 Days |
Enterprise Value | -$1.60M | $19.24B |
Dividend Yield | — | 3.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
SJM trades at $119.41, up 2.23% today, with a bearish technical signal but strong recent earnings beats. The company reported a net loss of $1.23 billion in 2025 despite revenue growth to $8.73 billion, though analysts project a return to profitability in 2026. A dividend of $1.12 is scheduled for September 2026, and institutional interest is rising, as seen with CalSTRS increasing its stake significantly in Q2 2026.
The outlook is mixed: analyst consensus is bullish with a $137.29 price target, but high debt and volatile profitability pose risks. Earnings momentum from recent beats and raised 2027 guidance support upside, yet investors must weigh margin pressures and competitive threats in the consumer staples sector against growth in segments like Uncrustables and Cafe Bustelo.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
